Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Asset Writedowns and Impairment: 2018-2025

Historic Asset Writedowns and Impairment for Aytu Biopharma (AYTU) over the last 5 years, with Sep 2025 value amounting to $300,000.

  • Aytu Biopharma's Asset Writedowns and Impairment rose 200.00% to $300,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year increase of 522.76%. This contributed to the annual value of $8.3 million for FY2025, which is 588.58% up from last year.
  • As of Q3 2025, Aytu Biopharma's Asset Writedowns and Impairment stood at $300,000, which was down 96.28% from $8.1 million recorded in Q2 2025.
  • In the past 5 years, Aytu Biopharma's Asset Writedowns and Impairment ranged from a high of $45.2 million in Q1 2022 and a low of $100,000 during Q4 2021.
  • In the last 3 years, Aytu Biopharma's Asset Writedowns and Impairment had a median value of $100,000 in 2025 and averaged $1.2 million.
  • As far as peak fluctuations go, Aytu Biopharma's Asset Writedowns and Impairment surged by 19,353.00% in 2021, and later tumbled by 99.78% in 2023.
  • Aytu Biopharma's Asset Writedowns and Impairment (Quarterly) stood at $100,000 in 2021, then skyrocketed by 2,500.00% to $2.6 million in 2022, then plummeted by 96.15% to $100,000 in 2023, then remained steady at $100,000 in 2024, then spiked by 200.00% to $300,000 in 2025.
  • Its Asset Writedowns and Impairment was $300,000 in Q3 2025, compared to $8.1 million in Q2 2025 and $100,000 in Q1 2025.